Aptar Enters into Agreement with Weihai Hengyu Medical Products
Weihai Hengyu Transaction Rationale
"We remain committed to
growing our business in
Asia and to creating an even
stronger local presence in
the region. This strategic
acquisition strengthens our
position to serve high
growth regional markets."
Stephan Tanda, Aptar President and CEO
◉
Components and devices market for
injectable drugs in China is forecasted to
have double-digit growth1
Regulatory support and safety supporting
trend towards high quality components
■ Vaccine development (due to COVID-19)
placing further emphasis on injectables
as the main delivery format
■ Aptar's strategic priority is to add
capabilities and capacity in high growth
markets (Asia/Elastomer Components)
Hengyu provides local Chinese
production with close proximity to
Chinese customers
Hengyu has over 23 years of experience
developing new elastomeric and plastic
component solutions for the injectable
drug delivery market
1 Source: IQVIA 2020, Internal models
Aptar
3View entire presentation